Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21979063 | 1.00 | P2RX7 (0.38) | P2RX7NOTUMEPAS1KMONOS3 | |
| SCHEMBL364870 | 0.78 | P2RX7 (0.36) | P2RX7NOTUMKMONOS3NOS2 | |
| SCHEMBL6805218 | 0.77 | AAK1 (0.38) | P2RX7NOTUMEPAS1KMONOS3 | |
| SCHEMBL31097846 | 0.75 | NOS2 (0.39) | P2RX7NOTUMKMONOS3NOS2 | |
| SCHEMBL22056622 | 0.75 | P2RX7 (0.38) | P2RX7NOTUM | |
| SCHEMBL6971787 | 0.75 | P2RX7 (0.34) | P2RX7NOTUMKMONOS3NOS2 | |
| SCHEMBL20088854 | 0.75 | NOS2 (0.39) | P2RX7NOTUMKMONOS3NOS2 | |
| SCHEMBL3100708 | 0.75 | NOS3 (0.35) | P2RX7NOTUMKMONOS3NOS2 | |
| SCHEMBL21598657 | 0.75 | KMO (0.35) | P2RX7NOTUMEPAS1KMONOS3 | |
| SCHEMBL20457055 | 0.72 | P2RX7 (0.36) | P2RX7NOTUMKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |